Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results-Reference-Cited by-同舟云学术

Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results

Published:2023-04-01 Issue:7 Volume:207 Page:929-935
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Dooley Kelly E.¹^ORCID,Hendricks Bronwyn²,Gupte Nikhil³,Barnes Grace⁴,Narunsky Kim²,Whitelaw Colleen²,Smit Tanya²,Ignatius Elisa H.⁴,Friedman Adine²,Dorman Susan E.⁵,Dawson Rodney²,

Affiliation:

1. Vanderbilt University Medical Center, Nashville, Tennessee;

2. Division of Pulmonology, Department of Medicine and University of Cape Town Lung Institute, University of Cape Town, Cape Town, South Africa;

3. Johns Hopkins India Private Limited, Pune, India;

4. School of Medicine, Johns Hopkins University, Baltimore, Maryland; and

5. Medical University of South Carolina, Charleston, South Carolina

Funder

U.S. Food and Drug Administration

National Institute of Allergy and Infectious Diseases

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202208-1475OC

Reference15 articles.

1. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

2. PA-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis

3. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

4. Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Safety and Efficacy of Prolonged Use of Bedaquiline for the Treatment of Patients with Pulmonary Multi-Drug Resistant/Rifampin-Resistant Tuberculosis: A Prospective, Cohort Study in China;Infection and Drug Resistance;2023-08

2. Recent advances in the treatment of tuberculosis;Clinical Microbiology and Infection;2023-07

3. Literature Highlights;The International Journal of Tuberculosis and Lung Disease;2023-06-01

4. Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis;American Journal of Respiratory and Critical Care Medicine;2023-04-01